How will Australia's traditional approach to health technology assessment manage a multi-million dollar one-time injection with the 'potential' to cure and add 40, 50, 60 or even 70 years of normal life expectancy? The US could lead the way. …
Do you value a lifetime benefit based on almost no evidence?
May 29, 2019 Latest NewsNews of the Day
Latest Video
New Stories
-
Lack of investment driving back-room deals
June 14, 2019 - - Latest News -
New technologies exposing flaws in HTA
June 14, 2019 - - Latest News -
Response on the use of 'opportunity cost'
June 14, 2019 - - Latest News -
Early, informed and high-quality engagement essential
June 14, 2019 - - Latest News -
Where was the 'frank and complete discussion' on rationing?
June 13, 2019 - - Latest News -
Gene technology an increasing focus
June 13, 2019 - - Latest News -
Evidence 'weaponised' through 'opportunity cost'
June 13, 2019 - - Latest News